Zoladex (Goserelin) Injection in India 2026: Complete Guide to Uses, Dosing, and Sourcing for Hospitals and Oncology Centres
Goserelin, sold under the brand name Zoladex, has been a cornerstone of hormone therapy for more than three decades, and it remains one of the most consistently prescribed LHRH agonists across Indian oncology and gynaecology practices in 2026. Despite how established the molecule is, hospital pharmacists and procurement teams still raise the same set of […]
Palbociclib, Ribociclib and Abemaciclib in India 2026 — Which CDK4/6 Inhibitor Is Right for Your Patient?
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called […]
Lutetium-177 PSMA Therapy for Prostate Cancer in India — Who Qualifies, How It Works, and Where to Access It in 2026
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work for a limited time in […]
Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication and was being described by […]